Theraclone Sciences secured an additional $8 million, bringing the total raised in its Series B funding round to $50 million. The Seattle biotech is developing two antibodies for severe flu and cytomegalovirus infection.
Published in Brief:
Attest Health Care Advisors
|NGS Provider Enrollment Rep||
National Government Services - WellPoint
|Program Manager II||
Tufts Health Plan/Network Health
|Director, Medicare Advantage/Medicare Part D Focus||
|Director of Clinical Research||
Regenesis Biomedical, Inc.